About this trial
Sepsis is a medical emergency whose prognosis depends on the early identification of patients at risk of septic shock, but the tools available in the Emergency Department remain insufficient. Neutrophils, key players in immunothrombosis, show alterations detectable via cell fluorescence (e.g., NE-SFL), which are strongly correlated with the severity of sepsis and septic DIC. The FLAMES study will evaluate, from the time of admission to the Emergency Department, the relevance of neutrophil fluorescence as an early biomarker of severity, either alone or integrated into an AI model based on the multiparametric data from the SthemA 801, with comparison to the Sysmex XN. It aims to address an unmet clinical need: the immediate stratification of the risk of severe forms of sepsis. Hypothesis: higher initial fluorescence will identify patients at risk of organ failure, septic shock, or DIC.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Admission to the ED
Suspected or proven infection defined by the prescription of antibiotic therapy within 24 hours following admission to the ED
Collection of an EDTA blood sample as part of routine care
Disqualifiers
Pregnancy or breastfeeding
Legal protection measure (guardianship, curatorship, judicial protection)
Trial design
Treatments tested in this trial
- Not listed